{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:10:20Z","timestamp":1779275420454,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Intravenous (IV) medications can be prepared using compounding devices to increase productivity, and reduce risks associated with aseptic compounding. This study evaluated the productivity and quality outcomes of the aseptic process for simulated batches of IV medications used in clinical practice produced using a semi-automated compounding device (Gri-fill; Grifols).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Simulated batches from 50 to 600 preparations were completed representing hazardous and non-hazardous drugs, including one-step single component (atropine sulfate, cisplatin) and multistep, multiple component (mitomycin C, piperacillin\/tazobactam, trastuzumab, 5-fluorouracil and gemcitabine). Productivity, device autonomy, quality of the aseptic process (media-fill test) and sterility of the preparations were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2024 final preparations and 460 intermediate products were compounded during 78 working hours. For low and high complexity level preparations, median (minimum-maximum) production speed was 1.3 (0.6\u20131.7) and 3.7 (2.6\u20134.3) min per preparation, respectively. The longest process (36.2\u2005min\/bag) was the preparation of a simulated gemcitabine 3\u2005L bulk solution bag, which included reconstitution of vials and filling the bulk bag. All operational errors (0.6%) were resolved autonomously by the user. None of the 883 media fill preparations showed microbiological growth and all 114 analyzed preparations passed the sterility test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using a semi-automated compounding device, preparation efficiency of IV medications ranged from 14 preparations\/h for multicomponent preparations from vials requiring reconstitution, to 100 preparations\/h for low complexity preparations using a bulk solution bag. The aseptic processes demonstrated the absence of microbial growth in all tested preparations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241304009","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:45:27Z","timestamp":1733370327000},"page":"622-631","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Productivity and aseptic process evaluation during batch production simulation of intravenous medications using a semi-automated compounding device"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-0247","authenticated-orcid":false,"given":"Ana C","family":"Riestra","sequence":"first","affiliation":[{"name":"Fundaci\u00f3n Onkologikoa"},{"name":"Department of Medicine, Faculty of Health Sciences, University of Deusto, Donostia, Gipuzkoa, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaione","family":"Grisale\u00f1a","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Kiro Grifols S.L., Arrasate, Gipuzkoa, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiara","family":"Telleria","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Kiro Grifols S.L., Arrasate, Gipuzkoa, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Cajaraville","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Onkologikoa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2146\/sp140001"},{"key":"e_1_3_3_3_2","unstructured":"EU guidelines to good manufacturing practice: medicinal products for human and veterinary use. Annex 1 manufacture of sterile medicinal products. https:\/\/ec.europa.eu\/health\/documents\/eudralex\/vol-4_en (accessed October 2021)."},{"key":"e_1_3_3_4_2","unstructured":"Pharmaceutical Compounding \u2013 USP Sterile Preparations General Chapter 797 https:\/\/www.usp.org\/compounding\/general-chapter-797 (accessed October 2021)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-020-00814-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-478"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp0108b"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1515\/pthp-2019-0008"},{"key":"e_1_3_3_9_2","first-page":"358","article-title":"Robotized compounding of oncology drugs in a hospital pharmacy","volume":"18","author":"Palma E","year":"2014","unstructured":"Palma E, Bufarini C. Robotized compounding of oncology drugs in a hospital pharmacy. Int J Pharm Compd 2014; 18: 358\u2013364. 2015\/01\/13.","journal-title":"Int J Pharm Compd"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2146\/sp150001"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000600"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2019-001948"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001745"},{"key":"e_1_3_3_14_2","unstructured":"General Information <1211> Sterilization and Steriliy Assurance of Compendial Articles General Chapters. https:\/\/www.usp.org\/."},{"key":"e_1_3_3_15_2","unstructured":"European Pharmacopeia (Ph. Eur.) 10th edition. Biological tests. 2.6.1 sterility."},{"key":"e_1_3_3_16_2","unstructured":"USP. Pharmaceutical Compounding \u2013 USP Sterile Preparations General Chapter 71. https:\/\/www.usp.org\/."},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"Carrez L. Qualification and Performance Evaluation of an Automated System for Compounding Injectable Cytotoxic Drugs. 2018.","DOI":"10.1515\/pthp-2018-0012"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218823911"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130489"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155221992841"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2015-000655"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-017-0081-z"},{"key":"e_1_3_3_23_2","unstructured":"ISO 13408-1:2008 Aseptic processing of health care products \u2014 Part 1: General requirements. https:\/\/www.iso.org\/standard\/59475.html."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219843322"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214565123"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241304009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241304009","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241304009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:55:19Z","timestamp":1779274519000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241304009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552241304009"],"URL":"https:\/\/doi.org\/10.1177\/10781552241304009","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}